Drug intelligence / Profile preview

KIN131A

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

KIN131A is an investigational small-molecule agonist of the cytosolic pattern recognition receptor retinoic acid-inducible gene I (RIG-I), being developed as an intratumoral immuno-oncology agent to stimulate innate antiviral-like signaling and promote antitumor immunity.[1][3] Preclinical data presented by Kineta Immuno-oncology show that KIN131A activates RIG-I signaling, leading to interferon-driven immune responses, inhibition of tumor growth, enhanced survival, and in some models complete tumor regression, indicating potential utility as a local immunotherapy for solid tumors.[1][3]

Targets

DDX58 (Retinoic acid-inducible gene I protein)

Beyond the preview

Go deeper on KIN131A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIN131A.

Explore the full profile